Shanghai Fosun Pharmaceutical (02196): The application for a new indication for Fumain has been accepted for listing and included in the priority review program.
Fosun Pharma (02196) announced that recently, its controlling subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (hereinafter referred to as "Fosun Pharmaceutical Industry") independently developed Fomatinib (generic name: Luvomebinate tablets) for the treatment of Type I neurofibromatosis (NF1) in adults with symptomatic, inoperable plexiform neurofibromas (PN) has applied for marketing approval, and the application has been accepted by the National Medical Products Administration and has been included in the priority review process.
Shanghai Fosun Pharmaceutical (02196) announced that its holding subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (hereinafter referred to as "Shanghai Fosun Pharmaceutical Industrial"), has applied for the marketing approval of its self-developed drug Fusomatinib (generic name: lumameditinib tablets) for the treatment of Type I Neurofibromatosis (NF1) adult patients with symptomatic and inoperable plexiform neurofibromas (PN) (hereinafter referred to as "new indication"). The application has been accepted by the National Medical Products Administration and has been included in the priority review process.
Related Articles
On February 5th, DMALL (02586) spent 2.6382 million Hong Kong dollars to repurchase 315,400 shares.
Yutong Heavy Industries (600817.SH) plans to grant no more than 6.76 million stock options with an exercise price of 10.45 yuan per share.
BAIRONG-W (06608) spent HK$1.0966 million to repurchase 100,000 shares on February 5th.
On February 5th, DMALL (02586) spent 2.6382 million Hong Kong dollars to repurchase 315,400 shares.
Yutong Heavy Industries (600817.SH) plans to grant no more than 6.76 million stock options with an exercise price of 10.45 yuan per share.
BAIRONG-W (06608) spent HK$1.0966 million to repurchase 100,000 shares on February 5th.
